REFERENCES
1. Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.
2. Hughes DA, Pastores GM. Gaucher disease. Seattle, WA: University of Washington; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1269/ [Last accessed on 18 Jun 2025].
3. D'Amore S, Page K, Donald A, et al. In-depth phenotyping for clinical stratification of Gaucher disease. Orphanet J Rare Dis. 2021;16:431.
4. Chen Y, Sud N, Hettinghouse A, Liu CJ. Molecular regulations and therapeutic targets of Gaucher disease. Cytokine Growth Factor Rev. 2018;41:65-74.
5. Koto Y, Sakai N, Lee Y, et al. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan. Mol Genet Metab. 2021;133:277-88.
6. Christomanou H, Aignesberger A, Linke RP. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Biol Chem Hoppe Seyler. 1986;367:879-90.
7. Hiraiwa M, Martin BM, Kishimoto Y, Conner GE, Tsuji S, O'Brien JS. Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside. Arch Biochem Biophys. 1997;341:17-24.
8. Chin SJ, Fuller M. Prevalence of lysosomal storage disorders in Australia from 2009 to 2020. Lancet Reg Health. 2022;19:100344.
9. Burton BK, Charrow J, Hoganson GE, et al. Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 2017;190:130-5.
10. Wasserstein MP, Caggana M, Bailey SM, et al. The New York pilot newborn screening program for lysosomal storage diseases: report of the First 65,000 Infants. Genet Med. 2019;21:631-40.
11. Saville JT, McDermott BK, Chin SJ, Fletcher JM, Fuller M. Expanding the clinical utility of glucosylsphingosine for Gaucher disease. J Inherit Metab Dis. 2020;43:558-63.
12. Dardis A, Michelakakis H, Rozenfeld P, et al. Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J Rare Dis. 2022;17:442.
13. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991;324:1464-70.
14. Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med. 2005;7:105-10.
15. Coutinho MF, Santos JI, Alves S. Less is more: substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci. 2016;17:1065.
16. Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37-44.
17. Mistry PK, Balwani M, Charrow J, et al. Long-term effectiveness of eliglustat treatment: a real-world analysis from the International Collaborative Gaucher Group Gaucher Registry. Am J Hematol. 2024;99:1500-10.
18. Daykin EC, Ryan E, Sidransky E. Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab. 2021;132:49-58.
19. Jiang W, Yi M, Maegawa GHB, Zhang H. Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease. J Hum Genet. 2020;65:345-9.
20. Narita A, Shirai K, Itamura S, et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Transl Neurol. 2016;3:200-15.
21. Maegawa GH, Tropak MB, Buttner JD, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem. 2009;284:23502-16.
22. Aries C, Lohmöller B, Tiede S, et al. Promising effect of high dose ambroxol treatment on neurocognition and motor development in a patient with neuropathic Gaucher disease 2. Front Neurol. 2022;13:907317.
23. Charkhand B, Scantlebury MH, Narita A, Zimran A, Al-Hertani W. Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease. Mol Genet Metab Rep. 2019;20:100476.
24. Chu SY, Chien CC, Hwu WL, Wang PJ, Chien YH. Early initiation of high-dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant. Blood Cells Mol Dis. 2020;81:102402.
25. Ciana G, Dardis A, Pavan E, et al. In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy. Mol Genet Metab Rep. 2020;25:100678.
26. Kim YM, Yum MS, Heo SH, et al. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. J Med Genet. 2020;57:124-31.
27. Bello AC, Cortez R. Early diagnosis of an infant with Gaucher's disease type 3. Case report. Blood. 2018;132:4950.
28. Ramadža DP, Zekušić M, Žigman T, et al. Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: a long-term outcome of two siblings. Eur J Paediatr Neurol. 2021;32:66-72.
29. Higashi K, Sonoda Y, Kaku N, et al. Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: a case report and literature review. Mol Genet Genomic Med. 2024;12:e2427.
30. Pawlinski L, Malecki MT, Kiec-Wilk B. The additive effect on the antiepileptic treatment of ambroxol in type 3 Gaucher patient. The early observation. Blood Cells Mol Dis. 2018;68:192-3.
31. Istaiti M, Revel-Vilk S, Becker-Cohen M, et al. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: investigator initiated registry based on real life data. Am J Hematol. 2021;96:545-51.
32. Schiffmann R, Sevigny J, Rolfs A, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020;43:1056-9.
33. Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol. 2016;80:766-75.
34. Luan Z, Li L, Higaki K, Nanba E, Suzuki Y, Ohno K. The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev. 2013;35:317-22.
35. Migdalska-Richards A, Ko WKD, Li Q, Bezard E, Schapira AHV. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse. 2017;71:e21967.
36. Migdalska-Richards A, Schapira AH. The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem. 2016;139 Suppl 1:77-90.
37. Babajani G, Tropak MB, Mahuran DJ, Kermode AR. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant. Mol Genet Metab. 2012;106:323-9.
38. Bendikov-Bar I, Maor G, Filocamo M, Horowitz M. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis. 2013;50:141-5.
39. Bendikov-Bar I, Ron I, Filocamo M, Horowitz M. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol Dis. 2011;46:4-10.
40. Ivanova MM, Changsila E, Turgut A, Goker-Alpan O. Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines. Am J Transl Res. 2018;10:3750-61.
41. Kopytova AE, Rychkov GN, Nikolaev MA, et al. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. Parkinsonism Relat Disord. 2021;84:112-21.
42. Pantoom S, Hules L, Schöll C, et al. Mechanistic Insight into the mode of action of acid β-glucosidase enhancer ambroxol. Int J Mol Sci. 2022;23:3536.
43. Zimran A, Altarescu G, Elstein D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol Dis. 2013;50:134-7.
44. Darling A, Irún P, Giraldo P, et al. Pediatric Gaucher disease with intermediate type 2-3 phenotype associated with parkinsonian features and levodopa responsiveness. Parkinsonism Relat Disord. 2021;91:19-22.
45. Schueler UH, Kolter T, Kaneski CR, Zirzow GC, Sandhoff K, Brady RO. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis. 2004;27:649-58.
46. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27-31.
47. Ismadi A, Shah M, Li K, Balasubramaniam S, Bhattacharya K. Phenotypic spectrum of neonatal Gaucher disease. J Inherit Metab Dis. 2021;44:1-461.
48. Gragnaniello V, Cazzorla C, Gueraldi D, et al. Light and shadows in newborn screening for lysosomal storage disorders: eight years of experience in northeast Italy. Int J Neonatal Screen. 2023;10:3.
49. Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166:172-7.
50. Chien YH, Lee NC, Chen PW, et al. Newborn screening for Morquio disease and other lysosomal storage diseases: results from the 8-plex assay for 70,000 newborns. Orphanet J Rare Dis. 2020;15:38.
51. Sawada T, Kido J, Sugawara K, et al. Newborn screening for Gaucher disease in Japan. Mol Genet Metab Rep. 2022;31:100850.
